Are Preoperative Kattan and Stephenson Nomograms Predicting Biochemical Recurrence after Radical Prostatectomy Applicable in the Chinese Population?

Abstract

Purpose. Kattan and Stephenson nomograms are based on the outcomes of patients with prostate cancer recruited in the USA, but their applicability to Chinese patients is yet to be validated. We aim at studying the predictive accuracy of these nomograms in the Chinese population. Patients and Methods. A total of 408 patients who underwent laparoscopic or open radical resection of prostate from 1995 to 2009 were recruited. The preoperative clinical parameters of these patients were collected, and they were followed up regularly with PSA monitored. Biochemical recurrence was defined as two or more consecutive PSA levels >0.4 ng/mL after radical resection of prostate or secondary cancer treatment. Results. The overall observed 5-year and 10-year biochemical recurrence-free survival rates were 68.3% and 59.8%, which was similar to the predicted values by the Kattan and Stephenson nomograms, respectively. The results of our study achieved a good concordance with both nomograms (Kattan: 5-years, 0.64; Stephenson: 5-years, 0.62, 10-years, 0.71). Conclusions. The incidence of prostate cancer in Hong Kong is increasing together with the patients' awareness of this disease. Despite the fact that Kattan nomograms were derived from the western population, it has been validated in our study to be useful in Chinese patients as well.

Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study

“…The inclusion criteria were (1) following the PCa diagnostic criteria of the European Association of Urology and the American Urological Association; (2) only single lesions visible by MRI and ultrasound were studied in order to reduce research bias; (3) patients with untreated primary prostate cancer; and (4) patients with complete clinical imaging data, good compliance, and long follow-up period. The exclusion criteria were as follows: (1) patients with tumors involving other organs; (2) patients with congenital heart disease, heart failure, liver and kidney insufficiency, history of allergies, and contraindications to enhanced imaging; and (3) patients with cognitive impairment [ 2 , 6 ]. This study has obtained the signed informed consents from the patients or their families and was approved by the Ethics Committee of Xiangyang No.…”